VARIOUS FORMS OF MUTANT p53 CONFER SENSITIVITY TO CISPLATIN AND DOXORUBICIN IN BLADDER CANCER CELLS
- 1 July 2001
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 166 (1) , 304-310
- https://doi.org/10.1016/s0022-5347(05)66150-2
Abstract
Conclusions These results indicated that the nature of p53 mutations may affect the cellular response to anticancer drugs and many forms of mutant p53 protein may enhance chemosensitivity through apoptotic or nonapoptotic pathways in bladder cancer cells.Keywords
This publication has 19 references indexed in Scilit:
- p53 Gene Mutation, Microsatellite Instability and Adjuvant Chemotherapy: Impact on Survival of 388 Patients with Dukes’ C Colon CarcinomaOncology, 2000
- p53 gene status modulates the chemosensitivity of non-small cell lung cancer cellsJournal of Biomedical Science, 2000
- Accumulation of Mutant p53V143A Modulates the Growth, Clonogenicity, and Radiochemosensitivity of Malignant Glioma Cells Independent of Endogenous p53 StatusExperimental Cell Research, 1999
- MVAC chemotherapy-induced apoptosis and p53 alterations in the rat model of bladder cancerUrology, 1998
- p53 and apoptosisSeminars in Cancer Biology, 1998
- p53, the Cellular Gatekeeper for Growth and DivisionCell, 1997
- p53; from inductive signal to cellular effectCurrent Opinion in Genetics & Development, 1997
- Clinical Implications of the p53 Tumor-Suppressor GeneNew England Journal of Medicine, 1993
- p53 function and dysfunctionCell, 1992
- p53 Mutations in Human CancersScience, 1991